Across TCGA pan-cancer cohorts, MYL4 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MYL4 data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MYL4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MYL4 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, LSCC, and LUAD are the cancer types where MYL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.421	0.214	.018	10	view →
LSCC	OS	Quartile	III,IV	0.531	0.983	.015	6	view →
LUAD	OS	Median	III,IV	0.750	0.998	.025	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MYL4 tumor-vs-normal RNA expression · all MYL4 data types